Skip to main content
Clinical Trials/NCT04224818
NCT04224818
Completed
Phase 3

Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders: A Prospective Randomized Controlled Trial

American University of Beirut Medical Center1 site in 1 country140 target enrollmentJuly 11, 2018

Overview

Phase
Phase 3
Intervention
Dual trigger
Conditions
Poor Ovarian Reserve
Sponsor
American University of Beirut Medical Center
Enrollment
140
Locations
1
Primary Endpoint
Number of mature oocytes (oocyte maturation rate)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This is a randomized controlled clinical trial to investigate the effect of dual trigger (hCG and GnRH agonist) on the final oocyte maturation compared to the standard hCG trigger in patients with poor ovarian reserve seeking IVF/ICSI treatment.

Detailed Description

Women with POR (Bologna criteria) manifest a very low follicular response to controlled ovarian stimulation irrespective of the stimulation protocol utilized. Dual triggering of oocyte maturation was shown to improve follicle collection yield and oocyte maturation in women with predicted normal ovarian response. These benefits have been attributed to the GnRHa-induced FSH surge believed to promote oocyte nuclear maturation and cumulus expansion. The aim of the study is to show whether the co-administration of a GnRH agonist and hCG for final oocyte maturation improve oocyte collection and maturation rate

Registry
clinicaltrials.gov
Start Date
July 11, 2018
End Date
August 30, 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Normal uterine cavity (as assessed by hysteroscopy or HSG).
  • Normal hormonal investigation: TSH, PRL.
  • Low ovarian reserve patients (AMH\<1.5ng/ml, AFC of 7 or less, 5 oocytes or less retrieved in a previous cycle)

Exclusion Criteria

  • Abnormal uterine cavity (Hysteroscopy or HSG)
  • Evidence of untreated endocrine disorders (abnormal TSH, prolactin, testosterone and androstenedione concentrations)

Arms & Interventions

Dual trigger

Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.

Intervention: Dual trigger

hCG (standard)

HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.

Intervention: hCG (standard)

Outcomes

Primary Outcomes

Number of mature oocytes (oocyte maturation rate)

Time Frame: 38 hrs

the ratio of MII oocytes to the number of collected oocytes

Number of oocytes retrieved (oocyte collection rate)

Time Frame: 38 hrs

the total number of oocytes retrieved divided by the number of follicles aspirated (diameter ≥10 mm) on the day of oocyte retrieval

Secondary Outcomes

  • Clinical pregnancy rate(7 weeks)
  • Implantation rate(7 weeks)
  • Miscarriage rate(12 weeks)
  • Fertilization rate(48 hrs)

Study Sites (1)

Loading locations...

Similar Trials